Biogen will release data from clinical trials for a few of its investigational treatments over the next few months, which should boost its shares, per JPMorgan.
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.